Sugi Predict

Sugi Predict / Compounds / SCHEMBL10097754

SCHEMBL10097754

SCHEMBL10097754

C/C=C\C[C@H](O)C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C

nearest known ligand 0.83

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TUBB4A P04350 2/20 0.83
▸ TUBB P07437 2/20 0.83
▸ TUBA3C P0DPH7 2/20 0.83
▸ TUBA1B P68363 2/20 0.83
▸ TUBA4A P68366 2/20 0.83
▸ TUBB4B P68371 2/20 0.83
▸ TUBB3 Q13509 2/20 0.83
▸ TUBB2A Q13885 2/20 0.83
▸ TUBB8 Q3ZCM7 2/20 0.83
▸ TUBA3E Q6PEY2 2/20 0.83
▸ TUBA1A Q71U36 2/20 0.83
▸ TUBA1C Q9BQE3 2/20 0.83
▸ TUBB6 Q9BUF5 2/20 0.83
▸ TUBB2B Q9BVA1 2/20 0.83
▸ TUBB1 Q9H4B7 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16274002 1.00 TUBB4A (0.83) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12895692 0.96 TUBB4A (0.77) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11947313 0.94 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16273882 0.94 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11947303 0.94 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24199008 0.94 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11947898 0.94 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13502908 0.94 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12895876 0.94 TUBB4A (0.76) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10097777 0.92 TUBB4A (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220168436-A1 ANTIBODY DRUG CONJUGATES PHARMA MAR SA (ES) 2022-06-02 — — US disclosed
US-11224663-B2 Antibody drug conjugates PHARMA MAR, S.A. (ES) 2022-01-18 — — US disclosed
EP-3003386-B1 ANTIBODY DRUG CONJUGATES PHARMA MAR SA (ES) 2019-10-16 — — EP disclosed
US-9827257-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2017-11-28 — — US disclosed
US-9750759-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2017-09-05 — — US disclosed
US-20160129128-A1 ANTIBODY DRUG CONJUGATES PHARMA MAR, S.A. (ES) 2016-05-12 — — US disclosed
EP-2597091-B1 Antitumoral Compounds PHARMA MAR SA (ES) 2016-04-20 — — EP disclosed
US-20150344454-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2015-12-03 — — US disclosed
US-20150342972-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2015-12-03 — — US disclosed
US-9187445-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2015-11-17 — — US disclosed
EP-2404913-A2 Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds Pharma Mar S.A. (ES) 2012-01-11 — — EP disclosed
EP-2404912-A2 Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds Pharma Mar S.A. (ES) 2012-01-11 — — EP disclosed
EP-2032551-B1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR SA (ES) 2011-08-31 — — EP disclosed
US-20110034549-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2011-02-10 — — US disclosed
US-20100048690-A2 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2010-02-25 — — US disclosed
US-20100048690-A2 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2010-02-25 — — US disclosed
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-23 — — US disclosed
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-23 — — US disclosed
WO-2009080761-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-02 — — WO disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344454-A1 ANTITUMORAL COMPOUNDS TP53, CCNY, RB1 TUBB4A 1373/4885TUBB 1877/4885TUBA3C 1855/4885
US-20220168436-A1 ANTIBODY DRUG CONJUGATES CD79B, OGFR, CD2 TUBB4A 114/4885TUBB 245/4885TUBA3C 460/4885
US-20100048690-A2 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS RPLP1, PKD1, KRAS TUBB4A 645/4885TUBB 1650/4885TUBA3C 1715/4885
US-20150342972-A1 ANTITUMORAL COMPOUNDS TP53, CCNY, RB1 TUBB4A 1373/4885TUBB 1877/4885TUBA3C 1855/4885
US-20160129128-A1 ANTIBODY DRUG CONJUGATES CD79B, OGFR, CD22 TUBB4A 109/4885TUBB 191/4885TUBA3C 494/4885
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS RPLP1, PKD1, KRAS TUBB4A 645/4885TUBB 1650/4885TUBA3C 1715/4885
US-11224663-B2 Antibody drug conjugates CD79B, OGFR, CD22 TUBB4A 114/4885TUBB 214/4885TUBA3C 487/4885
US-20110034549-A1 Antitumoral Compounds CCNY, RB1, TPD52L2 TUBB4A 1669/4885TUBB 2033/4885TUBA3C 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.